

# Progressive Pulmonary Fibrosis in Singapore



## Felicia Teo

**Organization** The Lung Clinic, Mount Elizabeth Medical Centre  
Division of Respiratory and Critical Care Medicine, National University Hospital

**Current Position** Senior Consultant Physician

### Educational background

2022	Fellow, Academy of Medicine, Singapore
2020	Fellow, Royal College of Physicians, London
2013	Specialist Accreditation in Intensive Care Medicine, Singapore
2010	European Diploma of Intensive Care, European Society of Intensive Care Medicine
2008	Specialist Accreditation in Respiratory Medicine, Singapore
2002	Member, Royal College of Physicians, London

### Professional experience

2022-Present	Senior Consultant Physician, The Lung Clinic, Mount Elizabeth Medical Centre
2021-Present	Site Principal Investigator for ILD-Sing National Registry in National University Hospital
2009-2022	Consultant and Senior Consultant, Division of Respiratory & Critical Care Medicine, National University Hospital, Singapore
2015-2022	Clinical Lead, Set up First Interstitial Lung Disease Unit in National University Hospital
2014-2015	Fellow, Interstitial Lung Diseases Unit, Royal Brompton Hospital, Singapore

Progressive pulmonary fibrosis (PPF) is a devastating form of fibrosing interstitial lung disease (ILD) associated with high morbidity and mortality. The burden of this disease has not been well-described in Singapore. This presentation will share some updates on epidemiological characteristics of PPF from a single center in Singapore, as well as effects of anti-fibrotic therapy on clinical outcomes.